|
| |
| | Arch Otolaryngol Head Neck Surg -- Abstract: Cure of an Established Nonimmunogenic Tumor, SCC VII, With a Novel ... |
 | | From the Departments of OtolaryngologyHead and Neck Surgery (Dr Mandpe) and Surgery (Drs Tsung and Norton), University of California, San Francisco, and the Surgical Service Veterans Affairs Medical Center, San Francisco (Drs Mandpe, Tsung, and Norton). |  | | However, interleukin 12 treatment provided immunity to second |  | | 12 were successfully cured, and all cured mice resisted subsequent |
|
http://archotol.ama-assn.org/cgi/content/abstract/129/7/786
|
|
| |
| | Interleukin |
 | | Materials and Methods: Sixty-one CHC patients who were treated by fixed protocol of IFN therapy (IFN [alpha] 9-10 mega U/day for 2 weeks followed by 3 times/week for 22 weeks) and showed similar clinical activities were carefully chosen from 542 IFN-treated CHC and enrolled in this study. |  | | Identification of the underlying regulatory factors may lead to new therapeutic approaches in the treatment of these diseases. |  | | The aim of this study was determine the immunoregulatory functions of Interleukin 12 (IL-12) with regard to local cytokine production in human liver. |
|
http://www.hepatitis-c.de/interleu.htm
|
|
| |
| | T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated ... |
 | | Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan |  | | T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohns disease |  | | T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease -- Matsuoka et al. |
|
http://www.gutjnl.com/cgi/content/abstract/53/9/1303
|
|
| |
| | Interleukin-12 may induce remission in NHL patients, IL-12 - Lymphoma-net.org news |
 | | US researchers have called for further investigation into interleukin (IL)-12 - an immune molecule sometimes used as a drug therapy - to treat non-Hodgkin's lymphoma (NHL), after an early-stage study showed that the treatment induces remission in some patients. |  | | Interleukin-12 may induce remission in some NHL patients |  | | Anas Younes, from The University of Texas MD Anderson Cancer Center in Houston, Texas, and colleagues conducted a study to evaluate the effectiveness and toxicity of artificially produced human IL-12 in patients with relapsed and unresponsive NHL and Hodgkin's disease (HD). |
|
http://lymphoma-net.org/newshtml/27908.cfm
|
|
| |
| | Liste des titres (notices ISI) |
 | | The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. |  | | Immunomodulation by Quillaja saponaria adjuvant formulations: In vivo stimulation of interleukin 12 and its effects on the antibody response. |  | | Interferon alpha/beta and interleukin 12 responses to viral infections: Pathways regulating dendritic cell cytokine expression in vivo. |
|
http://www.inist.fr/ChercheursIllustres/Resultats/titresISITrinchieriG.html
|
|
| |
| | [No title] |
 | | The 12 ponse induced by locoregional, low-dose interleukin-2 (IL-2) therapy. |  | | Patients receive bolus interleukin-2 on days 1-5 and 8-12. |
|
http://www.ugr.es/~oncoterm/csdata/i_ileuki.txt
|
|
| |
| | [Frontiers in Bioscience 2, d12-26, January 1, 1997] |
 | | M.N. Manoussakis, G.K. Papadopoulos, A.A. Drosos and H.M. Moutsopoulos: Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. |  | | Overproduction of IL-6 by fibroblasts cultured from affected skin sites of patients with scleroderma. |  | | Better understanding of the pathways regulated by cytokines will allow the identification and/or development of agents for improved modulation of the inflammatory response for the treatment of autoimmune, infectious, and neoplastic diseases. |
|
http://www.bioscience.org/1997/v2/d/feghali1/htmls/12-26.htm
|
|
| |
| | Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma ... |
 | | Gollob JA, Mier JW, Veenstra K, et al: Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response. |  | | Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma |  | | Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. |
|
http://www.jco.org/cgi/content/full/21/13/2564
|
|
| |
| | World J Gastroenterol |
 | | Continuous release of interleukin 12 from microencapsulated engineered cells for colon cancer therapy |  | | Interleukin 12 gene transfer into skin distant from |  | | This result also showed that the approach for local and sustained release of interleukin 12 could induces both innate and adaptive antitumor immune responses resulting in significant growth suppression and metastases of tumor[29-31]. |
|
http://www.wjgnet.com/1007-9327/9/951.asp
|
|
| |
| | Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate ... |
 | | Prostate Cancer Gene Therapy: Comparison of Adenovirus-mediated Expression of Interleukin 12 with Interleukin 12 plus B7-1 for in Situ Gene Therapy and Gene-modified, Cell-based Vaccines |  | | Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma |  | | Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression |
|
http://www.pnas.org/cgi/content/full/94/20/10889
|
|
| |
| | Interleukin 12 and autoimmune diabetes - Nature Genetics |
 | | Overall, these results point to several mediators and effector mechanisms that contribute to T1D (ref. 12), and it is likely that the genetic absence of IL-12 or IFN- |  | | Interleukin 12 and autoimmune diabetes - Nature Genetics |  | | This finding has potential implications for the prediction of at-risk individuals and, perhaps, for the implementation of prevention strategies relevant to several autoimmune diseases. |
|
http://www.nature.com/ng/journal/v27/n2/full/ng0201_131.html
|
|
| |
| | Methods for inducing interleukin-12 and a type1/Th1 T-cell response (US6517839) |
 | | Heinzel, F.P. et al., "Recombinant Interleukin 12 Cures Mice Infected with Leishmania major," Journal of Experimental Medicine, May 1993, 177:1505-9. |  | | Zhang, Ming et al., "Interleukin 12 at the Site of Disease in Tuberculosis," The Journal of Clinical Investigation, Apr. 1994, 93:1733-9. |  | | D'Andrea, Annalisa et al., "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," The Journal of Expreimental Medicine, Nov. 1992, 176:1387-98. |
|
http://www.delphion.com/details?pn=US06517839__
|
|
| |
| | Horst Ibelgaufts'COPE: Cytokines Online Pathfinder Encyclopaedia |
 | | Anderson R et al Construction and biological characterization of an interleukin 12 fusion protein (flexi 12): delivery to acute myeloid leukemic blasts using adeno associated virus. |  | | Bigda J et al Interleukin 12 augments natural killer-cell mediated cytotoxicity in hairy cell leukemia. |  | | Journal of Experimental Medicine 178: 413-8 (1993); Kiniwa M et al Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. |
|
http://www.copewithcytokines.de/cope.cgi?005130
|
|
| |
| | Interleukin 12 p40 Production by Barrier Epithelial Cells during Airway Inflammation -- Walter et al. 193 (3): 339 -- ... |
 | | (references 4, 5, 7, 9, 10, and 12 and unpublished observations). |  | | /ß- and interleukin 12-mediated pathways in promoting T cell interferon |  | | Plevy, S.E., Gemberling, H.M., Hsu, S., Dorner, A.J., and Smale, S.T. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. |
|
http://www.jem.org/cgi/content/full/193/3/339
|
|
| |
| | National Cancer Institute - Clinical Trials (PDQ®) |
 | | Biopsy-proven residual disease at least 12 weeks after myeloablative therapy |  | | Recurrent disease, evidenced by any of the following: |  | | Cohort A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8, 10, and 12. |
|
http://www.nci.nih.gov/clinicaltrials/NANT-2001-01
|
|
| |
| | Interleukin-12 (IL-12) Production in Whole Blood Cultures From Human Immunodeficiency Virus-Infected Individuals ... |
 | | Chehimi J, Paganin C, Frank I, Chouaib S, Starr SE, Trinchieri G: Interleukin-12 in the pathogenesis and therapy of HIV disease. |  | | Denis M, Ghadirian E: Dysregulation of interleukin 8, interleukin 10, and interleukin 12 release by alveolar macrophages from HIV type 1-infected subjects. |  | | Meyaard L, Hovenkamp E, Otto SA, Miedema F: IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. |
|
http://www.bloodjournal.org/cgi/content/full/89/2/570
|
|
| |
| | BBC NEWS Health Vaccine 'may stop heart disease' |
 | | Professor Packard said the main problem with vaccines was that they targeted the immune system, which is already thought to be involved in triggering the inflammation process seen in heart disease. |  | | It targets a chemical messenger called interleukin 12, thought to play an important part in the inflammation process. |  | | Scientists at Leiden University in the Netherlands recently reported a breakthrough in their search for a vaccine. |
|
http://news.bbc.co.uk/go/newsFeedXML/moreover/-/1/hi/health/4115223.stm
|
|
|